EPIPHARM SIGNED
Development of a ncRNA DNA Methylation Kit for Treatment Guidance in Cancer of Unknown Primary
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0EPIPHARM project word cloud
Explore the words cloud of the EPIPHARM project. It provides you a very rough idea of what is the project "EPIPHARM" about.
Project "EPIPHARM" data sheet
The following table provides information about the project.
| Coordinator |
FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE
Organization address contact info |
| Coordinator Country | Spain [ES] |
| Total cost | 149˙345 € |
| EC max contribution | 149˙345 € (100%) |
| Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
| Code Call | ERC-2016-PoC |
| Funding Scheme | ERC-POC |
| Starting year | 2017 |
| Duration (year-month-day) | from 2017-02-01 to 2018-07-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE | ES (L'HOSPITALET DE LLOBREGAT) | coordinator | 119˙345.00 |
| 2 | XENOPAT SL | ES (HOSPITALET DE LLOBREGAT) | participant | 30˙000.00 |
Map
Project objective
The innovative idea behind the EPIPHARM (EPIgenetics of PHARMacogenetics) project is to develop a package demonstrating the feasibility of a high-throughput tool for epigenotyping Cancer of Unknown Primary (CUP) to identify a drug sensitivity fingerprint based in the DNA methylation profile of non-coding RNA (ncRNA) loci. CUPs are a heterogeneous group of cancers defined by the presence of metastatic disease with no identified primary tumor at presentation. The CUP outcome is extremely poor with an expected death within the first six months of the diagnosis. CUP has been reported to comprise approximately 5% of all cancer cases in the world. Despite the introduction of new image technologies and immunohistochemistry methods, more than 50% of CUPs remain anonymous regarding their primary tumor site of origin and, as mentioned, their prognoses are dismal. For most patients with CUP, recommended treatments involves just empiric chemotherapy, usually with a taxane/platinum or gemcitabine/platinum regimens that achieve the described modest clinical benefit. Thus, it is necessary to have better tools to guide the pharmacological treatment of CUP cases. As part of the ERC Advanced Grant “Epigenetic Disruption on Non-Coding RNAs in Human Cancer” (EPINORC) we identified CpG methylation changes in a wide variety of ncRNAs (microRNAs, lincRNAs, T-UCRs, snoRNAs, piRNAs...) that showed a tumor-type specific pattern that has allowed the successful development of the EPICUP assay for the diagnoses of CUPs that it has been licensed and it is undergoing final clinical validation. In the current EPIPHARM Proof of Concept (PoC) proposal, we plan to optimize a ncRNA DNA methylation assay that includes a user-friendly and cost effective approach to improve the therapy of CUP cases by providing a more personalized drug treatment to an extent that will make it interesting commercially for the health providers and their associated company partners.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2018 |
Michäel Duruisseaux, Anna MartÃnez-Cardús, Maria E Calleja-Cervantes, Sebastian Moran, Manuel Castro de Moura, Veronica Davalos, David Piñeyro, Montse Sanchez-Cespedes, Nicolas Girard, Marie Brevet, Etienne Giroux-Leprieur, Coraline Dumenil, Monica Pradotto, Paolo Bironzo, Enrica Capelletto, Silvia Novello, Alexis Cortot, Marie-Christine Copin, Niki Karachaliou, Maria Gonzalez-Cao, Sergio Peralta, Luis M Montuenga, Ignacio Gil-Bazo, Iosune Baraibar, Maria D Lozano, Mar Varela, Jose C Ruffinelli, Ramon Palmero, Ernest Nadal, Teresa Moran, Lidia Perez, Immaculada Ramos, Qingyang Xiao, Agustin F Fernandez, Mario F Fraga, Marta Gut, Ivo Gut, Cristina Teixidó, Noelia Vilariño, Aleix Prat, Noemi Reguart, Amparo Benito, Pilar Garrido, Isabel Barragan, Jean-François Emile, Rafael Rosell, Elisabeth Brambilla, Manel Esteller Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis published pages: 771-781, ISSN: 2213-2600, DOI: 10.1016/S2213-2600(18)30284-4 |
The Lancet Respiratory Medicine 6/10 | 2019-04-03 |
| 2017 |
Sebastián Moran, Anna Martinez-Cardús, Stergios Boussios, Manel Esteller Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary published pages: 682-694, ISSN: 1759-4774, DOI: 10.1038/nrclinonc.2017.97 |
Nature Reviews Clinical Oncology 14/11 | 2019-04-03 |
| 2018 |
Humberto J. Ferreira, Veronica Davalos, Manuel Castro de Moura, Marta Soler, Montserrat Perez-Salvia, Alberto Bueno-Costa, Fernando Setien, Sebastian Moran, Alberto Villanueva, Manel Esteller Circular RNA CpG island hypermethylation-associated silencing in human cancer published pages: , ISSN: 1949-2553, DOI: 10.18632/oncotarget.25673 |
Oncotarget 9/49 | 2019-04-03 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EPIPHARM" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "EPIPHARM" are provided by the European Opendata Portal: CORDIS opendata.